BioNTech (NASDAQ:BNTX) Shares Gap Down to $100.53

BioNTech SE (NASDAQ:BNTX)’s share price gapped down before the market opened on Tuesday . The stock had previously closed at $100.53, but opened at $96.38. BioNTech shares last traded at $100.39, with a volume of 166,704 shares traded.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on BNTX shares. Deutsche Bank Aktiengesellschaft raised BioNTech from a “hold” rating to a “buy” rating and set a $95.00 price target on the stock in a research note on Wednesday, August 7th. HSBC raised BioNTech from a “hold” rating to a “buy” rating in a research report on Friday, August 2nd. TD Cowen dropped their price target on BioNTech from $98.00 to $85.00 and set a “hold” rating on the stock in a research report on Tuesday, August 6th. JPMorgan Chase & Co. lowered their target price on BioNTech from $94.00 to $91.00 and set an “underweight” rating on the stock in a research note on Thursday, August 15th. Finally, HC Wainwright restated a “buy” rating and set a $113.00 price target on shares of BioNTech in a report on Tuesday, August 27th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $109.09.

BioNTech Stock Up 1.1 %

The company has a quick ratio of 7.40, a current ratio of 7.54 and a debt-to-equity ratio of 0.01. The firm has a fifty day simple moving average of $85.08 and a 200-day simple moving average of $89.26. The company has a market capitalization of $24.16 billion, a P/E ratio of 201.06 and a beta of 0.23.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings results on Monday, August 5th. The company reported ($3.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.02) by ($1.34). The firm had revenue of $128.70 million during the quarter, compared to analyst estimates of $134.98 million. BioNTech had a negative net margin of 18.69% and a negative return on equity of 2.54%. The business’s revenue for the quarter was down 23.3% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.86) EPS. On average, equities research analysts expect that BioNTech SE will post -2.8 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Harding Loevner LP bought a new position in shares of BioNTech in the 4th quarter valued at about $410,984,000. Candriam S.C.A. raised its stake in shares of BioNTech by 261.2% during the 2nd quarter. Candriam S.C.A. now owns 578,998 shares of the company’s stock worth $46,526,000 after purchasing an additional 418,695 shares in the last quarter. Point72 Asset Management L.P. boosted its holdings in shares of BioNTech by 283.5% in the 2nd quarter. Point72 Asset Management L.P. now owns 461,711 shares of the company’s stock valued at $37,103,000 after buying an additional 341,311 shares during the last quarter. Primecap Management Co. CA grew its stake in shares of BioNTech by 2.8% in the fourth quarter. Primecap Management Co. CA now owns 4,763,453 shares of the company’s stock valued at $502,735,000 after buying an additional 131,490 shares in the last quarter. Finally, SG Americas Securities LLC increased its holdings in BioNTech by 610.5% during the first quarter. SG Americas Securities LLC now owns 70,143 shares of the company’s stock worth $6,471,000 after buying an additional 60,270 shares during the last quarter. Institutional investors own 15.52% of the company’s stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.